Cargando…

Development of an Innovative Intradermal siRNA Delivery System Using a Combination of a Functional Stearylated Cytoplasm-Responsive Peptide and a Tight Junction-Opening Peptide

As a new category of therapeutics for skin diseases including atopic dermatitis (AD), nucleic acids are gaining importance in the clinical setting. Intradermal administration is noninvasive and improves patients′ quality of life. However, intradermal small interfering RNA (siRNA) delivery is difficu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibaraki, Hisako, Kanazawa, Takanori, Takashima, Yuuki, Okada, Hiroaki, Seta, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274127/
https://www.ncbi.nlm.nih.gov/pubmed/27669207
http://dx.doi.org/10.3390/molecules21101279
Descripción
Sumario:As a new category of therapeutics for skin diseases including atopic dermatitis (AD), nucleic acids are gaining importance in the clinical setting. Intradermal administration is noninvasive and improves patients′ quality of life. However, intradermal small interfering RNA (siRNA) delivery is difficult because of two barriers encountered in the skin: intercellular lipids in the stratum corneum and tight junctions in the stratum granulosum. Tight junctions are the major barrier in AD; therefore, we focused on functional peptides to devise an intradermal siRNA delivery system for topical skin application. In this study, we examined intradermal siRNA permeability in the tape-stripped (20 times) back skin of mice or AD-like skin of auricles treated with 6-carboxyfluorescein-aminohexyl phosphoramidite (FAM)-labeled siRNA, the tight junction modulator AT1002, and the functional cytoplasm-responsive stearylated peptide STR-CH(2)R(4)H(2)C by using confocal laser microscopy. We found that strong fluorescence was observed deep and wide in the epidermis and dermis of back skin and AD-like ears after siRNA with STR-CH(2)R(4)H(2)C and AT1002 treatment. After 10 h from administration, brightness of FAM-siRNA was significantly higher for STR-CH(2)R(4)H(2)C + AT1002, compared to other groups. In addition, we confirmed the nontoxicity of STR-CH(2)R(4)H(2)C as a siRNA carrier using PAM212 cells. Thus, our results demonstrate the applicability of the combination of STR-CH(2)R(4)H(2)C and AT1002 for effective intradermal siRNA delivery.